The Design and Development of Improved Fluorocarbon-Based Products for use in Medicine and Biology
- 1 January 1994
- journal article
- research article
- Published by Taylor & Francis in Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
- Vol. 22 (2) , 215-234
- https://doi.org/10.3109/10731199409117416
Abstract
Fluorocarbons and other highly fluorinated materials offer considerable potential in diagnosis and therapeutics due to their unique physical properties, chemical inertness, capacity to transport oxygen and drugs, and ability to function as contrast agents. Applications such as hemodilution and organ preservation, cancer diagnosis and chemotherapy, x-ray imaging of the lymph nodes and magnetic resonance imaging of the GI tract, cardioplegia and reperfusion, the treatment of myocardial ischemia and respiratory distress syndrome, as well as drug delivery, all obviously require different product characteristics, calling for an array of products which may range from different neat fluorocarbons to diversely formulated emulsions, or fluorinated vesicles. Substantial progress has been made in terms of emulsion efficacy and stability. Stable, ready-to-use, concentrated, though fluid, injectable emulsions have now been developed. Small doses of such emulsions were demonstrated to be highly efficient in tissue oxygenation. Commercial-scale manufacturing including heat sterilization of these emulsions have been achieved. Some of the side-effects, which generally relate to the normal response of the organism to injected particles, have been reduced, and their mechanism determined. Further efforts will undoubtedly be devoted to understanding and adjusting emulsion properties for optimal efficacy in each identified application and to maximizing benefit vs side-effect ratio. Our ability to modulate in vivo recognition, intravascular persistence and subsequent biodistribution of fluorocarbon droplets, vesicles and other particulate matter in the organism is still in its infancy. Proper control of these characteristics would further extend the potential of such products for medical uses. It is essential that no effort be spared to increase our general understanding of their physicochemical properties and in vivo “physiology“.Keywords
This publication has 17 references indexed in Scilit:
- Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results.American Journal of Roentgenology, 1993
- Artificial Oxygen Carrying Blood SubstitutesPublished by Springer Nature ,1992
- Fluorocarbon‐Based in vivo Oxygen Transport and Delivery SystemsVox Sanguinis, 1991
- Results of the Phase III Trials with Imagent® GI as an Oral Magnetic Resonance Contrast AgentInvestigative Radiology, 1991
- Intraluminal contrast enhancement and MR visualization of the bowel wall: Efficacy of PFOBJournal of Magnetic Resonance Imaging, 1991
- Perfluorocarbon-associated gas exchangeCritical Care Medicine, 1991
- Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imagingAmerican Journal of Roentgenology, 1989
- Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide.Radiology, 1989
- Reassessment of Criteria for the Selection of Perfluorochemicals for Second‐Generation Blood Substitutes: Analysis of Structure/Property RelationshipsArtificial Organs, 1984
- Solubility and transport phenomena in perfluorochemicals relevant to blood substitution and other biomedical applicationsPublished by Walter de Gruyter GmbH ,1982